2018 IMPAACT Annual Meeting Treatment Scientific Committee Presentations

Treatment Scientific Committee

Monday, 18 June 2018

Welcome and Overview of Treatment Scientific Agenda

Elaine Abrams and Ted Ruel


Update on Dolutegravir

Overview of Recent Findings on Dolutegravir

Elaine Abrams

Implications of Recent DTG Findings for IMPAACT 2010/VESTED

Lameck Chinula

Panel Discussion: Clinical Implications and Community Perspectives

Moderator: Elaine Abrams

Panelists: Linda Barlow-Mosha, Yuitiang Durier, Maximina Jokonya, Ted Ruel


Treatment Committee Scientific Updates

P1026s, Focus on TAF: Pharmacokinetic Properties of Antiretrovirals Therapy During Pregnancy

Mark Mirochnick


P1093: Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572 (Dolutegravir), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

Ted Ruel


P1101: Phase I/II Dose-Finding, Safety, Tolerance, & PK Study of Raltegravir-Containing ART Regimen in HIV-Infected & TB Co-Infected Children

Paul Krogstad


P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

Adrie Bekker


P1110: A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-Exposed Infants at High Risk

Diana Clarke


Updates on Treatment Studies Enrolling, Pending and In-development

Elaine Abrams and
Ted Ruel